ArticlePLOS global public health2025
The role of molecular xenomonitoring for assessing the impact of Ivermectin, Diethylcarbamazine Citrate and Albendazole triple-drug treatment against lymphatic filariasis: A cross-sectional study in the Kenyan coastal region.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphatic Filariasis (LF) is a mosquito-borne disease primarily caused by the filarial parasite Wuchereria bancrofti. The triple-drug therapy of Ivermectin, Diethylcarbamazine Citrate and Albendazole (IDA) has been adopted to accelerate LF elimination of LF as a public health problem, particularly in areas where onchocerciasis is not co-endemic. In Kenya, IDA was administered to endemic communities in Jomvu sub-County (Mombasa) and Lamu County in 2018 and 2019. The impact of IDA was assessed using Molecular Xenomonitoring (MX), which involves detecting W. bancrofti DNA in mosquito pools via quantitative PCR (qPCR). MX surveys were conducted at baseline (2018) and at IDA impact survey 1 (IIS-1) in 2021 after two treatment rounds. Mosquitoes were collected from 30 randomly and 5-9 purposively selected villages per area. Traps used included CDC light, Gravid, and BioGents (BG) traps at baseline, and only CDC light and Gravid traps at IIS-1. Mosquitoes were sorted by genus and pooled in up to 25 per pool. DNA was extracted and analyzed by qPCR. Filarial DNA prevalence was estimated using PoolTools v0.1.4. Concurrently, human infection was assessed using filariasis test strips (FTS) to detect circulating filarial antigen (CFA). At baseline, 37,732 mosquitoes were collected: 0.07% Anopheles, 2.3% Aedes, and 97.6% Culex. Of 486 pools tested, 30 (0.26%) were positive for W. bancrofti DNA. At IIS-1, 71,634 mosquitoes were collected: 0.46% Anopheles and 99.5% Culex. Of 1,695 pools tested, 22 (0.06%) were positive. Significant reductions were observed in filarial DNA in mosquitoes (76.9%, p < 0.001) and human antigenemia (52.1%, p = 0.004) after two treatment rounds. This study demonstrates a substantial decline in LF infection following two rounds of IDA. It also highlights molecular xenomonitoring as a sensitive and non-invasive tool for monitoring LF elimination progress. We recommend its integration into national LF control programs as a complementary surveillance method post-MDA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.